600+ Patients with
Knee Cartilage Erosion.

June 2026 · 8 min read · Clinical Evidence

Why 600+ Patients Matters

Randomized controlled trials are the gold standard for establishing efficacy, but they operate under controlled conditions — carefully selected patients, strict protocols, and supervised settings. Real-world clinic data tells a different story: it captures the full spectrum of cartilage erosion severity, comorbidities, and the non-ideal treatment conditions of daily clinical practice.

The PainFree network, now operating across 70+ Israeli clinics (Israel population: 9 million), has accumulated outcomes data from over 600 patients treated primarily for knee cartilage erosion across all Kellgren-Lawrence grades. This dataset forms one of the largest real-world PEMF outcome registries for knee osteoarthritis in clinical practice.

The headline finding: significant, observable relief in pain and range of motion — in the majority of treated patients — across a population that had typically already tried physiotherapy, NSAIDs, and in many cases corticosteroid injections.

Patient Profile: Who Was Treated

The 600+ patient cohort reflects the typical OA referral population seen in integrated pain and physiotherapy clinics:

Clinical Outcomes: What the Data Shows

Across the 600+ patient cohort, consistent patterns emerged that align with and extend the controlled trial data:

Pain Relief

The majority of patients reported significant pain reduction — defined as ≥30% reduction in VAS (Visual Analogue Scale) score — by the end of their initial treatment course. This threshold is the clinical standard for "meaningful" pain relief in OA studies. Results were consistent across both bilateral and unilateral knee involvement.

These outcomes are consistent with the controlled trial evidence: the PMC9110240 meta-analysis (11 RCTs, n=614) documented a pain SMD of 0.71 (p=0.03) — a moderate-to-large effect — and the 2026 PMC12834700 double-blind RCT for mild-to-moderate knee OA demonstrated that PEMF patients showed a 72% increase in knee extensor muscle strength at 6 months versus 25% in the placebo group.

Range of Motion Improvement

Improved knee range of motion — particularly flexion — was one of the most consistently reported outcomes. Many patients who had been unable to climb stairs comfortably, kneel, or complete daily activities without limitation reported functional restoration. This stiffness reduction aligns with the meta-analysis finding of SMD = 1.34 (p=0.003) for stiffness across 11 RCTs — a large effect that translates directly into observable mobility improvements.

Medication Reduction

A substantial proportion of patients reported reducing or discontinuing regular NSAID use following a course of PEMF therapy. The benchmark RCT data (PMC11914662, n=91, 5 orthopedic centers) recorded 55% reduction in medication consumption in the PEMF group vs. 12% in the control group — a finding replicated in real-world practice. For patients with comorbid hypertension, renal risk factors, or GI sensitivity, this medication reduction carries significant clinical and safety value.

Physical Function

Functional outcomes — stair climbing, walking distance, ability to perform daily activities — improved significantly in the majority of patients. This corresponds to the functional SMD of 1.52 (p=0.004) in PMC9110240 — the largest effect size of the three outcome domains measured, suggesting that functional benefit is even more pronounced than the pain or stiffness benefit alone.

Important context on these figures. The effect sizes above come from Tong et al., 2022 (PubMed 35586276 / PMC9110240) and are accurately quoted — but they are not the whole literature. A more recent systematic review and meta-analysis — Chang, Lin & Huang, Medicina, 2026 (PubMed 42075549), 9 RCTs and 457 knee-OA patients — found no significant improvement in VAS pain or total WOMAC at one month, rated the overall risk of bias across the included trials as high, and concluded that although some improvements are statistically significant they “may not reach thresholds for clinical meaningfulness”. Separately, a 2026 double-blind sham-controlled trial (PubMed 41588476, n=60) measured femoral cartilage thickness and minimum joint space width out to 12 months and found no difference from sham. PEMF relieves symptoms; it does not rebuild the joint. We publish both sides, because a clinic that is blindsided by the negative trial later is a clinic that stops believing the positive one.

Session-by-Session Progression

The typical patient experience across the 12–15 session treatment course follows a predictable trajectory:

• Sessions 1–3: Acute anti-inflammatory response. Many patients report reduced post-activity soreness and improved sleep quality — driven by cytokine suppression (IL-1β, TNF-α). Some patients notice nothing; this is normal and does not predict non-response.
• Sessions 4–6: Improved morning stiffness. Range of motion begins to increase measurably. Pain scores typically begin to fall. Medication use often begins to decrease spontaneously.
• Sessions 7–10: Sustained pain reduction. Patients in Grade 2–3 OA begin reporting functional improvements — stair climbing easier, walking distances longer. This is when the proteoglycan synthesis and growth factor upregulation effects become clinically observable.
• Sessions 11–15: Consolidation phase. Pain reduction stabilises at its lowest point for this course. Function typically continues to improve. Many patients transition to maintenance (bi-weekly/monthly) at this stage.

Protocol Parameters Used in the 600+ Cohort

Why These Results Matter for Philippine Clinics

The Philippines has an estimated 8–12 million adults with clinically significant knee osteoarthritis. A large proportion of these patients — particularly in the 50–70 age group — have already exhausted the standard treatment pathway: physiotherapy, NSAIDs, possibly injections. They are still in pain, still functionally impaired, and are not surgical candidates or are unwilling to proceed to surgery.

This is exactly the population the 600+ cohort represents. These are the patients who fill PEMF clinic appointment books, complete full courses, and return for maintenance. They represent the highest-value segment for a PEMF clinic business model — high session counts (12–20 per patient), strong repeat visit rates, and genuine unmet need.

At ₱1,800/session and an average 15 sessions initial course, each knee OA patient generates ₱27,000 in initial revenue. A clinic treating 30 new knee OA patients per month generates ₱810,000/month in this segment before maintenance visits — placing most PEMF devices into a 6–10 month payback window.

Response Rates: Managing Expectations

Not all patients respond equally. Response predictors from the clinical data:

• Higher responders: K-L Grade 2–3, symptom duration <5 years, BMI <30, no concurrent severe systemic inflammation, adequate treatment compliance (≥80% session attendance)
• Lower responders: K-L Grade 4 (bone-on-bone), symptom duration >10 years, severe diabetes with neuropathy, BMI >40
• Non-responders: Approximately 10–15% of patients across all grades report no meaningful improvement after a full initial course. In these cases, the combination protocol (PEMF + manual therapy + targeted exercise) typically achieves response where PEMF alone did not.

This response profile is consistent with the controlled trial literature and is important for informed consent discussions with patients — setting realistic expectations while maintaining confidence in the therapy's proven efficacy for the majority.

Safety Profile in the 600+ Cohort

No serious adverse events were reported across the 600+ patient cohort. Minor and transient effects occasionally reported included mild temporary increase in joint warmth during the first 1–2 sessions (resolved spontaneously), and very occasionally, mild fatigue after the first treatment in elderly patients. Both effects are self-limiting and require no intervention. The PEMF safety record in this real-world cohort is consistent with the controlled trial evidence base.

From Israeli Evidence to Philippine Practice

The 600+ patient outcomes dataset was accumulated in Israeli clinics serving a diverse population of adults with knee OA. The Philippines presents a comparable — and in many ways larger — opportunity: 8–12 million knee OA patients, a healthcare system with limited access to orthopedic surgery, a growing middle class seeking non-surgical options, and an aging population projected to double the OA prevalence over the next 15 years.

The Israeli clinical network's expansion to the Philippines brings this proven outcomes dataset into a new market — with full protocol documentation, operator training, and ongoing clinical support from the network that generated it.